日韩欧美 a级,国产又色又爽又刺激在线观看,偷偷色噜狠狠狠狠的777米奇,浮妇高潮喷白浆视频

Talmapimod

    98%

Talmapimod

源葉(MedMol)
S84867
309913-83-5
C27H30ClFN4O3
513
品牌 貨號(hào) 產(chǎn)品規(guī)格 價(jià)格(RMB) 庫(kù)存(上海) 北京 武漢 南京 購(gòu)買(mǎi)數(shù)量
源葉(MedMol) S84867-5mg 98% ¥990.00元 預(yù)計(jì)交期:2-3天 - - -
源葉(MedMol) S84867-10mg 98% ¥1720.00元 預(yù)計(jì)交期:2-3天 - - -
源葉(MedMol) S84867-25mg 98% ¥3600.00元 預(yù)計(jì)交期:2-3天 - - -
源葉(MedMol) S84867-50mg 98% ¥5200.00元 預(yù)計(jì)交期:2-3天 - - -
產(chǎn)品介紹 參考文獻(xiàn) 質(zhì)檢證書(shū)(COA) 摩爾濃度計(jì)算器 相關(guān)產(chǎn)品

產(chǎn)品介紹

Talmapimod (SCIO-469) is an orally active, selective, and ATP-competitive p38α inhibitor with an IC50 of 9 nM. Talmapimod shows about 10-fold selectivity over p38β, and at least 2000-fold selectivity over a panel of 20 other kinases, including other MAPKs
產(chǎn)品描述: Talmapimod (SCIO-469) is an orally active, selective, and ATP-competitive p38α inhibitor with an IC50 of 9 nM. Talmapimod shows about 10-fold selectivity over p38β, and at least 2000-fold selectivity over a panel of 20 other kinases, including other MAPKs
靶點(diǎn): p38α:9 nM (IC50);p38β:90 nM (IC50);p38MAPK
體內(nèi)研究: Targeting p38α MAPK with Talmapimod (SCIO-469) decreases myeloma burden in addition to preventing the development of myeloma bone disease. Talmapimod inhibits multiple myeloma growth and prevents bone disease in the 5T2MM and 5T33MM models. Talmapimod (10-90 mg/kg; p.o.; twice daily orally for 14 days) dose-dependently reduced tumor growth and also dose-dependently reduced weight of the palpable tumors at termination Animal Model: Six-week-old male triple immune-deficient BNX mice (RPMI-8226 MM palpable tumors) Dosage: P.o.; twice daily orally for 14 days Administration: 10, 30, 90 mg/kg Result: Dose-dependently reduced tumor growth.
參考文獻(xiàn): 1. Hideshima T et al. p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene. 2004 Nov 18, 23(54), 8766-76. 2. Navas T, et al. Inhibition of p38alpha MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment. Leuk Lymphoma. 2008 Oct;49(10):1963-75. 3. Vanderkerken K et al. Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease,reduces tumor burden, and increases survival in murine models of multiple myeloma. Cancer Res. 2007 May 15;67(10):4572-7. 4. Medicherla S, et al. p38alpha-selective MAP kinase inhibitor reduces tumor growth in mouse xenograft models of multiple myeloma. Anticancer Res. 2008 Nov-Dec;28(6A):3827-33.
溶解性: Soluble  in  DMSO
保存條件: 2-8℃
配置溶液濃度參考:
1mg 5mg 10mg
1 mM 1.949 ml 9.747 ml 19.493 ml
5 mM 0.39 ml 1.949 ml 3.899 ml
10 mM 0.195 ml 0.975 ml 1.949 ml
50 mM 0.039 ml 0.195 ml 0.39 ml
注意: 部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶(hù)參考交流研究之用。

參考文獻(xiàn)

質(zhì)檢證書(shū)(COA)

如何獲取質(zhì)檢證書(shū)(COA)?
請(qǐng)輸入貨號(hào)和一個(gè)與之匹配的批號(hào)。
例如:
批號(hào):JS298415 貨號(hào):S20001-25g
在貨品標(biāo)簽上如何找到貨號(hào)和批號(hào)?

摩爾濃度計(jì)算器

質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)

=
×
×

相關(guān)產(chǎn)品